Publication | Open Access

Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial

OphthalmologyChronic InflammatoryMedicineSubcutaneous EfgartigimodClinical TrialsNeurologyMultiple SclerosisDermatologySclerodermaNeuroimmunology